{
    "markdown": "<a id='09888ccd-947f-4e17-b75f-9dcf7218b237'></a>\n\nAl: Joint decisions have to be made to come up with a starting dose based on information.\n\n<a id='2be8ede4-0bb9-4b93-bbf5-f4cebad33167'></a>\n\nWRAP- UP\nEpidemiologic studies to be conducted starting at the preclinical development stage. This can be done depending on how successful you expect the drug to be. For example, to assess class effect, Epidemiologic studies from the outset are needed to characterize what is known about the drug in the class.\n\n<a id='f09e19b9-8272-4816-afc5-e207b25528b6'></a>\n\nGlyn: Good studies with placebo controlled data are more beneficial; open label long term studies do not define this drug safety profile. Looking at the placebos subjects course long term gives valuable data.\n\n<a id='fc328acf-ae89-4de1-8512-ec4480d3f985'></a>\n\n### Plans / Next Steps/ Closing Comments\n\nQuestion: Agency will come out with guidelines in September, 2004. How do we formalize the company's standpoint?\n\n<a id='58ea1e8d-55c3-497a-9cc8-2300e199ec7b'></a>\n\nAnswer: We do risk management all the time. We simply need to put it down on paper.\n\n*   White paper- concept paper needs to be created\n    Put data together in better ways: yearly getogether to formalize these perhaps at the time of IND Annual Report.\n    Example: 559 uterine CA issue: nothing has been done for this unlike the bladder CA issue\n*   On preclinical review, need to work these details out\n*   Global Reorganization: Global Safety Meeting in Japan is a good place to start discussion. There is little manpower in safety in TCI. Clinical and Safety divisions should have a joint say in things. Create a global story in Actos. Need product stewardship. Glyn & Cal to further discuss rasing issue at the Global Safety Mtg.\n*   Need a multidisciplinary team approach (Astro Zeneca) to create awareness of safety issues as they develop. Consider yearly (or other periodic) joint meetings between Clinical and Safety to look at and analyze safety data.\n\n<a id='8248c0b7-d5b6-4877-b113-dcedf2c81f47'></a>\n\nTakeda Forum Risk Management\nMarch 22, 2004\n\n<a id='84aab49f-2e8d-4f28-ab16-c897b7ac0864'></a>\n\n4\n\n<a id='edaccca1-b36c-47ff-bdea-5feb0818a1c1'></a>\n\nConfidential \u2013 Subject to Protective Order\n\n<a id='a4c931a5-74f9-4420-ac59-a47c4158023c'></a>\n\nTAK-BAROND-00208934\nProduced in MDL on 09/02/12\n\n<a id='bcffbd3e-f71c-44eb-ac51-47778923f35f'></a>\n\nSource: https://www.indusP0156-00004s.ucsf.edu/docs/gmjf0226",
    "chunks": [
        {
            "markdown": "<a id='09888ccd-947f-4e17-b75f-9dcf7218b237'></a>\n\nAl: Joint decisions have to be made to come up with a starting dose based on information.",
            "type": "text",
            "id": "09888ccd-947f-4e17-b75f-9dcf7218b237",
            "grounding": {
                "box": {
                    "left": 0.19123253226280212,
                    "top": 0.15807095170021057,
                    "right": 0.7814129590988159,
                    "bottom": 0.1798035204410553
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='2be8ede4-0bb9-4b93-bbf5-f4cebad33167'></a>\n\nWRAP- UP\nEpidemiologic studies to be conducted starting at the preclinical development stage. This can be done depending on how successful you expect the drug to be. For example, to assess class effect, Epidemiologic studies from the outset are needed to characterize what is known about the drug in the class.",
            "type": "text",
            "id": "2be8ede4-0bb9-4b93-bbf5-f4cebad33167",
            "grounding": {
                "box": {
                    "left": 0.19188082218170166,
                    "top": 0.188029482960701,
                    "right": 0.8228763341903687,
                    "bottom": 0.261283278465271
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='f09e19b9-8272-4816-afc5-e207b25528b6'></a>\n\nGlyn: Good studies with placebo controlled data are more beneficial; open label long term studies do not define this drug safety profile. Looking at the placebos subjects course long term gives valuable data.",
            "type": "text",
            "id": "f09e19b9-8272-4816-afc5-e207b25528b6",
            "grounding": {
                "box": {
                    "left": 0.19225171208381653,
                    "top": 0.2692957818508148,
                    "right": 0.820044994354248,
                    "bottom": 0.3177604377269745
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='fc328acf-ae89-4de1-8512-ec4480d3f985'></a>\n\n### Plans / Next Steps/ Closing Comments\n\nQuestion: Agency will come out with guidelines in September, 2004. How do we formalize the company's standpoint?",
            "type": "text",
            "id": "fc328acf-ae89-4de1-8512-ec4480d3f985",
            "grounding": {
                "box": {
                    "left": 0.19219452142715454,
                    "top": 0.3259164094924927,
                    "right": 0.8223255276679993,
                    "bottom": 0.3883429765701294
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='58ea1e8d-55c3-497a-9cc8-2300e199ec7b'></a>\n\nAnswer: We do risk management all the time. We simply need to put it down on paper.\n\n*   White paper- concept paper needs to be created\n    Put data together in better ways: yearly getogether to formalize these perhaps at the time of IND Annual Report.\n    Example: 559 uterine CA issue: nothing has been done for this unlike the bladder CA issue\n*   On preclinical review, need to work these details out\n*   Global Reorganization: Global Safety Meeting in Japan is a good place to start discussion. There is little manpower in safety in TCI. Clinical and Safety divisions should have a joint say in things. Create a global story in Actos. Need product stewardship. Glyn & Cal to further discuss rasing issue at the Global Safety Mtg.\n*   Need a multidisciplinary team approach (Astro Zeneca) to create awareness of safety issues as they develop. Consider yearly (or other periodic) joint meetings between Clinical and Safety to look at and analyze safety data.",
            "type": "text",
            "id": "58ea1e8d-55c3-497a-9cc8-2300e199ec7b",
            "grounding": {
                "box": {
                    "left": 0.19329491257667542,
                    "top": 0.3949405252933502,
                    "right": 0.8257317543029785,
                    "bottom": 0.6814519166946411
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='8248c0b7-d5b6-4877-b113-dcedf2c81f47'></a>\n\nTakeda Forum Risk Management\nMarch 22, 2004",
            "type": "text",
            "id": "8248c0b7-d5b6-4877-b113-dcedf2c81f47",
            "grounding": {
                "box": {
                    "left": 0.19349618256092072,
                    "top": 0.8137674927711487,
                    "right": 0.3650595545768738,
                    "bottom": 0.8396955132484436
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='84aab49f-2e8d-4f28-ab16-c897b7ac0864'></a>\n\n4",
            "type": "marginalia",
            "id": "84aab49f-2e8d-4f28-ab16-c897b7ac0864",
            "grounding": {
                "box": {
                    "left": 0.5012876987457275,
                    "top": 0.8153713345527649,
                    "right": 0.5199815034866333,
                    "bottom": 0.8306404948234558
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='edaccca1-b36c-47ff-bdea-5feb0818a1c1'></a>\n\nConfidential \u2013 Subject to Protective Order",
            "type": "text",
            "id": "edaccca1-b36c-47ff-bdea-5feb0818a1c1",
            "grounding": {
                "box": {
                    "left": 0.12602166831493378,
                    "top": 0.8699629902839661,
                    "right": 0.3690488934516907,
                    "bottom": 0.8879929184913635
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='a4c931a5-74f9-4420-ac59-a47c4158023c'></a>\n\nTAK-BAROND-00208934\nProduced in MDL on 09/02/12",
            "type": "text",
            "id": "a4c931a5-74f9-4420-ac59-a47c4158023c",
            "grounding": {
                "box": {
                    "left": 0.7423865795135498,
                    "top": 0.8681243062019348,
                    "right": 0.9356627464294434,
                    "bottom": 0.9016408324241638
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='bcffbd3e-f71c-44eb-ac51-47778923f35f'></a>\n\nSource: https://www.indusP0156-00004s.ucsf.edu/docs/gmjf0226",
            "type": "marginalia",
            "id": "bcffbd3e-f71c-44eb-ac51-47778923f35f",
            "grounding": {
                "box": {
                    "left": 0.21661868691444397,
                    "top": 0.9781095385551453,
                    "right": 0.7835265398025513,
                    "bottom": 1.0002236366271973
                },
                "page": 0
            }
        }
    ],
    "splits": [
        {
            "class": "full",
            "identifier": "full",
            "pages": [
                0
            ],
            "markdown": "<a id='09888ccd-947f-4e17-b75f-9dcf7218b237'></a>\n\nAl: Joint decisions have to be made to come up with a starting dose based on information.\n\n<a id='2be8ede4-0bb9-4b93-bbf5-f4cebad33167'></a>\n\nWRAP- UP\nEpidemiologic studies to be conducted starting at the preclinical development stage. This can be done depending on how successful you expect the drug to be. For example, to assess class effect, Epidemiologic studies from the outset are needed to characterize what is known about the drug in the class.\n\n<a id='f09e19b9-8272-4816-afc5-e207b25528b6'></a>\n\nGlyn: Good studies with placebo controlled data are more beneficial; open label long term studies do not define this drug safety profile. Looking at the placebos subjects course long term gives valuable data.\n\n<a id='fc328acf-ae89-4de1-8512-ec4480d3f985'></a>\n\n### Plans / Next Steps/ Closing Comments\n\nQuestion: Agency will come out with guidelines in September, 2004. How do we formalize the company's standpoint?\n\n<a id='58ea1e8d-55c3-497a-9cc8-2300e199ec7b'></a>\n\nAnswer: We do risk management all the time. We simply need to put it down on paper.\n\n*   White paper- concept paper needs to be created\n    Put data together in better ways: yearly getogether to formalize these perhaps at the time of IND Annual Report.\n    Example: 559 uterine CA issue: nothing has been done for this unlike the bladder CA issue\n*   On preclinical review, need to work these details out\n*   Global Reorganization: Global Safety Meeting in Japan is a good place to start discussion. There is little manpower in safety in TCI. Clinical and Safety divisions should have a joint say in things. Create a global story in Actos. Need product stewardship. Glyn & Cal to further discuss rasing issue at the Global Safety Mtg.\n*   Need a multidisciplinary team approach (Astro Zeneca) to create awareness of safety issues as they develop. Consider yearly (or other periodic) joint meetings between Clinical and Safety to look at and analyze safety data.\n\n<a id='8248c0b7-d5b6-4877-b113-dcedf2c81f47'></a>\n\nTakeda Forum Risk Management\nMarch 22, 2004\n\n<a id='84aab49f-2e8d-4f28-ab16-c897b7ac0864'></a>\n\n4\n\n<a id='edaccca1-b36c-47ff-bdea-5feb0818a1c1'></a>\n\nConfidential \u2013 Subject to Protective Order\n\n<a id='a4c931a5-74f9-4420-ac59-a47c4158023c'></a>\n\nTAK-BAROND-00208934\nProduced in MDL on 09/02/12\n\n<a id='bcffbd3e-f71c-44eb-ac51-47778923f35f'></a>\n\nSource: https://www.indusP0156-00004s.ucsf.edu/docs/gmjf0226",
            "chunks": [
                "09888ccd-947f-4e17-b75f-9dcf7218b237",
                "2be8ede4-0bb9-4b93-bbf5-f4cebad33167",
                "f09e19b9-8272-4816-afc5-e207b25528b6",
                "fc328acf-ae89-4de1-8512-ec4480d3f985",
                "58ea1e8d-55c3-497a-9cc8-2300e199ec7b",
                "8248c0b7-d5b6-4877-b113-dcedf2c81f47",
                "84aab49f-2e8d-4f28-ab16-c897b7ac0864",
                "edaccca1-b36c-47ff-bdea-5feb0818a1c1",
                "a4c931a5-74f9-4420-ac59-a47c4158023c",
                "bcffbd3e-f71c-44eb-ac51-47778923f35f"
            ]
        }
    ],
    "grounding": {
        "09888ccd-947f-4e17-b75f-9dcf7218b237": {
            "box": {
                "left": 0.19123253226280212,
                "top": 0.15807095170021057,
                "right": 0.7814129590988159,
                "bottom": 0.1798035204410553
            },
            "page": 0,
            "type": "chunkText"
        },
        "2be8ede4-0bb9-4b93-bbf5-f4cebad33167": {
            "box": {
                "left": 0.19188082218170166,
                "top": 0.188029482960701,
                "right": 0.8228763341903687,
                "bottom": 0.261283278465271
            },
            "page": 0,
            "type": "chunkText"
        },
        "f09e19b9-8272-4816-afc5-e207b25528b6": {
            "box": {
                "left": 0.19225171208381653,
                "top": 0.2692957818508148,
                "right": 0.820044994354248,
                "bottom": 0.3177604377269745
            },
            "page": 0,
            "type": "chunkText"
        },
        "fc328acf-ae89-4de1-8512-ec4480d3f985": {
            "box": {
                "left": 0.19219452142715454,
                "top": 0.3259164094924927,
                "right": 0.8223255276679993,
                "bottom": 0.3883429765701294
            },
            "page": 0,
            "type": "chunkText"
        },
        "58ea1e8d-55c3-497a-9cc8-2300e199ec7b": {
            "box": {
                "left": 0.19329491257667542,
                "top": 0.3949405252933502,
                "right": 0.8257317543029785,
                "bottom": 0.6814519166946411
            },
            "page": 0,
            "type": "chunkText"
        },
        "8248c0b7-d5b6-4877-b113-dcedf2c81f47": {
            "box": {
                "left": 0.19349618256092072,
                "top": 0.8137674927711487,
                "right": 0.3650595545768738,
                "bottom": 0.8396955132484436
            },
            "page": 0,
            "type": "chunkText"
        },
        "84aab49f-2e8d-4f28-ab16-c897b7ac0864": {
            "box": {
                "left": 0.5012876987457275,
                "top": 0.8153713345527649,
                "right": 0.5199815034866333,
                "bottom": 0.8306404948234558
            },
            "page": 0,
            "type": "chunkMarginalia"
        },
        "edaccca1-b36c-47ff-bdea-5feb0818a1c1": {
            "box": {
                "left": 0.12602166831493378,
                "top": 0.8699629902839661,
                "right": 0.3690488934516907,
                "bottom": 0.8879929184913635
            },
            "page": 0,
            "type": "chunkText"
        },
        "a4c931a5-74f9-4420-ac59-a47c4158023c": {
            "box": {
                "left": 0.7423865795135498,
                "top": 0.8681243062019348,
                "right": 0.9356627464294434,
                "bottom": 0.9016408324241638
            },
            "page": 0,
            "type": "chunkText"
        },
        "bcffbd3e-f71c-44eb-ac51-47778923f35f": {
            "box": {
                "left": 0.21661868691444397,
                "top": 0.9781095385551453,
                "right": 0.7835265398025513,
                "bottom": 1.0002236366271973
            },
            "page": 0,
            "type": "chunkMarginalia"
        }
    },
    "metadata": {
        "filename": "gmjf0226_4.png",
        "org_id": null,
        "page_count": 1,
        "duration_ms": 12436,
        "credit_usage": 3.0,
        "job_id": "yghny96mfphmqkpm5yndr9oj6",
        "version": "dpt-2-20250919"
    }
}